TrialPharmacology research & perspectives2021

TROIKA-1: A double-blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin

Martin Demarchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.